<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03772028</url>
  </required_header>
  <id_info>
    <org_study_id>M17OVH</org_study_id>
    <nct_id>NCT03772028</nct_id>
  </id_info>
  <brief_title>Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</brief_title>
  <acronym>OVHIPEC-2</acronym>
  <official_title>Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or&#xD;
      without hyperthermic intraperitoneal chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to prove that treatment with primary cytoreductive surgery in&#xD;
      combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive&#xD;
      surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage&#xD;
      III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no&#xD;
      residual disease, or residual disease up to 2.5 mm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled, open-label, multicenter phase III trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year after last patient last visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>1 year after last patient last visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>30 days after end of treatment</time_frame>
    <description>toxicity of extra treatment compared standaard treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost evaluation</measure>
    <time_frame>1 year after lplv</time_frame>
    <description>cost evaluation based measured by quality adjusted life year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>conventional surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Primary cytoreductive surgery without HIPEC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary cytoreductive surgery with HIPEC with cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>HIPEC with cisplatin after cytoreductive surgery</description>
    <arm_group_label>HIPEC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  candidate for primary CRS&#xD;
&#xD;
          -  histological or cytological proven FIGO stage III primary epithelial ovarian,&#xD;
             fallopian tube, or extra-ovarian cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of previous malignancies within 5 years prior to inclusion&#xD;
&#xD;
          -  FIGO stage IV disease&#xD;
&#xD;
          -  complete primary cytoreduction is impossible&#xD;
&#xD;
          -  prior treatment for the current malignancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Willemien van Driel, MD, PhD</last_name>
    <phone>031 20 512 7918</phone>
    <email>OVHIPEC@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lot Aronson</last_name>
    <phone>031 20 512 7918</phone>
    <email>OVHIPEC@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MSKCC New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bhavani Ramesh</last_name>
      <email>rameshb@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Oliver Zivanovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette Magnusson</last_name>
      <email>mette.magnusson@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Berit Jul Mosgaard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils Lyon Sud (CHU Lyon)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Cloud</last_name>
      <email>virginie.cloud@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Naoual Bakrin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabila Bouazza</last_name>
      <email>Nabila.Bouazza@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Emmanuel Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest, ICO Nantes)</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Palardy</last_name>
      <email>Thierry.Palardy@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Bourgin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaud Lourenco</last_name>
      <email>Lourenco.Thibaud@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Ferron Gwenael</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital, Dublin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terri Martin</last_name>
      <email>tmartin@mater.ie</email>
    </contact>
    <investigator>
      <last_name>Donal Brennan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola, Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierandrea De Iaco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico A Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Deamicis</last_name>
      <email>andrea.deamicis@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Anna Fagotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lot Aronson, PhD candidate</last_name>
      <email>l.aronson@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ruby van Stein, PhD candidate</last_name>
      <email>r.v.stein@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Willemien van Driel, dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center (LUMC)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud MC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Academic Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asa michelgard palmquist</last_name>
      <email>asa.michelgard_palmquist@ucr.uu.se</email>
    </contact>
    <investigator>
      <last_name>Marta Lomnytska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>December 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2018</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>HIPEC</keyword>
  <keyword>OVHIPEC</keyword>
  <keyword>primary debulking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

